Clinical trial

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

NCT04534725

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-12-17

PhasePHASE3

Study timeline

Study start (actual)2020-12-17Date precision: day

Registry last updated2023-08-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cancerunresolved

Covid19unresolved

Respiratory Viral Infectionunresolved

Interventions

Interferon alfaDRUG

SelinexorDRUG · verified · RxNorm: selinexor

LenzilumabDRUG

Sponsors & collaborators

Peter MacCallum Cancer Centre, Australialead sponsor

Mapped research locations

MelbourneVictoria, Australia3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04534725 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.